Brief: MGC Pharmaceuticals Posts FY Revenue Of A$3.4 Mln

Argent BioPharma

31/08/2023 09:24

Aug 31 (Reuters) - MGC Pharmaceuticals Ltd  MXC.AX :
    * FY REVENUE A$3.4 MILLION VERSUS A$4.7 MILLION
    * FY NET LOSS FROM ORDINARY ACTIVITIES AFTER TAX
ATTRIBUTABLE
A$21.1 MILLION VERSUS LOSS A$17.1 MILLION

Source text for Eikon:  ID:nASX5gN8R1 
Further company coverage:  MXC.AX 

 ((Reuters.Briefs@thomsonreuters.com;))